Literature DB >> 21419658

The impact of heart failure severity at time of listing for cardiac transplantation on survival in pediatric cardiomyopathy.

Ranae L Larsen1, Charles E Canter, David C Naftel, Margaret Tressler, David N Rosenthal, Elizabeth D Blume, William T Mahle, Delphine Yung, William R Morrow, E John Orav, James D Wilkinson, Jeffrey A Towbin, Stephen E Lipshultz.   

Abstract

BACKGROUND: The survival benefit of heart transplantation in adult heart failure is greatest for the sickest patients and negligible for patients not requiring inotropic or mechanical support. We hypothesized a similar survival benefit of heart transplantation for childhood cardiomyopathies with heart failure.
METHODS: A merged data set of children registered in both the Pediatric Cardiomyopathy Registry and the Pediatric Heart Transplant Study was used to assess differences in mortality before and after transplant in patients with different levels of heart failure severity. Severity was scored 2 if mechanical ventilatory or circulatory support was required, 1 if intravenous inotropes were required, or 0 if no support was required.
RESULTS: For 332 eligible children, 12-month mortality after listing was 9% for those with a severity score of 0 (n = 105), 16% with a score of 1 (n = 118), and 26% with a score of 2 (n = 109; p = 0.002) with a 3%, 8%, and 20% mortality with severity scores at listing of 0, 1, and 2, respectively, occurring before transplant. Patients listed with a score of 0 frequently deteriorated: 50% received an allograft or died before transplant with severity scores of 1 or 2. The risk of deterioration increased with previous surgery (relative risk, 3.84; p = 0.03) in the short-term and with lower left ventricular mass z-score at time of presentation (relative risk, 1.74; p = 0.003) in the longer-term.
CONCLUSION: Pediatric cardiomyopathy patients who require high levels of support receive a survival benefit from heart transplantation that is not shared by patients not requiring intravenous inotropic or mechanical support.
Copyright © 2011 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21419658      PMCID: PMC3110638          DOI: 10.1016/j.healun.2011.01.718

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  26 in total

1.  Design and implementation of the North American Pediatric Cardiomyopathy Registry.

Authors:  M A Grenier; S K Osganian; G F Cox; J A Towbin; S D Colan; P R Lurie; L A Sleeper; E J Orav; S E Lipshultz
Journal:  Am Heart J       Date:  2000-02       Impact factor: 4.749

Review 2.  Biomarkers in heart failure.

Authors:  Eugene Braunwald
Journal:  N Engl J Med       Date:  2008-05-15       Impact factor: 91.245

3.  Lessons learned from the pediatric heart transplant study.

Authors:  Daphne T Hsu; David C Naftel; Steven A Webber; William R Morrow; Charles E Canter; Richard E Chinnock; Mary Lynne Clark; James K Kirklin
Journal:  Congenit Heart Dis       Date:  2006-05       Impact factor: 2.007

4.  Registry of the International Society for Heart and Lung Transplantation: Twelfth Official Pediatric Heart Transplantation Report-2009.

Authors:  Richard Kirk; Leah B Edwards; Paul Aurora; David O Taylor; Jason D Christie; Fabienne Dobbels; Anna Y Kucheryavaya; Axel O Rahmel; Josef Stehlik; Marshall I Hertz
Journal:  J Heart Lung Transplant       Date:  2009-10       Impact factor: 10.247

5.  Effects of the 2006 U.S. thoracic organ allocation change: analysis of local impact on organ procurement and heart transplantation.

Authors:  Jose N Nativi; Abdallah G Kfoury; Craig Myrick; Melissa Peters; Dale Renlund; Edward M Gilbert; Feras Bader; Arun K Singhal; Melanie Everitt; Patrick Fisher; David A Bull; Craig Selzman; Josef Stehlik
Journal:  J Heart Lung Transplant       Date:  2009-09-26       Impact factor: 10.247

Review 6.  Indications for heart transplantation in pediatric heart disease: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young; the Councils on Clinical Cardiology, Cardiovascular Nursing, and Cardiovascular Surgery and Anesthesia; and the Quality of Care and Outcomes Research Interdisciplinary Working Group.

Authors:  Charles E Canter; Robert E Shaddy; Daniel Bernstein; Daphne T Hsu; Maryanne R K Chrisant; James K Kirklin; Kirk R Kanter; Robert S D Higgins; Elizabeth D Blume; David N Rosenthal; Mark M Boucek; Karen C Uzark; Alan H Friedman; Allen H Friedman; James K Young
Journal:  Circulation       Date:  2007-01-29       Impact factor: 29.690

7.  Waiting list mortality among children listed for heart transplantation in the United States.

Authors:  Christopher S D Almond; Ravi R Thiagarajan; Gary E Piercey; Kimberlee Gauvreau; Elizabeth D Blume; Heather J Bastardi; Francis Fynn-Thompson; T P Singh
Journal:  Circulation       Date:  2009-01-26       Impact factor: 29.690

8.  Outcomes of children with cardiomyopathy listed for transplant: a multi-institutional study.

Authors:  Anne I Dipchand; David C Naftel; Brian Feingold; Robert Spicer; Delphine Yung; Beth Kaufman; James K Kirklin; Tina Allain-Rooney; Daphne Hsu
Journal:  J Heart Lung Transplant       Date:  2009-09-26       Impact factor: 10.247

9.  Use of multiple biomarkers to improve the prediction of death from cardiovascular causes.

Authors:  Björn Zethelius; Lars Berglund; Johan Sundström; Erik Ingelsson; Samar Basu; Anders Larsson; Per Venge; Johan Arnlöv
Journal:  N Engl J Med       Date:  2008-05-15       Impact factor: 91.245

10.  Carvedilol for children and adolescents with heart failure: a randomized controlled trial.

Authors:  Robert E Shaddy; Mark M Boucek; Daphne T Hsu; Robert J Boucek; Charles E Canter; Lynn Mahony; Robert D Ross; Elfriede Pahl; Elizabeth D Blume; Debra A Dodd; David N Rosenthal; Jeri Burr; Bernie LaSalle; Richard Holubkov; Mary Ann Lukas; Lloyd Y Tani
Journal:  JAMA       Date:  2007-09-12       Impact factor: 56.272

View more
  3 in total

Review 1.  Stem cell therapy for pediatric dilated cardiomyopathy.

Authors:  Sarah M Selem; Sunjay Kaushal; Joshua M Hare
Journal:  Curr Cardiol Rep       Date:  2013-06       Impact factor: 2.931

Review 2.  Pediatric cardiomyopathies: causes, epidemiology, clinical course, preventive strategies and therapies.

Authors:  Steven E Lipshultz; Thomas R Cochran; David A Briston; Stefanie R Brown; Peter J Sambatakos; Tracie L Miller; Adriana A Carrillo; Liat Corcia; Janine E Sanchez; Melissa B Diamond; Michael Freundlich; Danielle Harake; Tamara Gayle; William G Harmon; Paolo G Rusconi; Satinder K Sandhu; James D Wilkinson
Journal:  Future Cardiol       Date:  2013-11

Review 3.  Issues in solid-organ transplantation in children: translational research from bench to bedside.

Authors:  Steven E Lipshultz; Jayanthi J Chandar; Paolo G Rusconi; Alessia Fornoni; Carolyn L Abitbol; George W Burke; Gaston E Zilleruelo; Si M Pham; Elena E Perez; Ruchika Karnik; Juanita A Hunter; Danielle D Dauphin; James D Wilkinson
Journal:  Clinics (Sao Paulo)       Date:  2014       Impact factor: 2.365

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.